The identification of novel targets and therapeutic agents in the treatment of triple negative breast cancer.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1013525

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Triple negative breast cancer constitutes 15-20% of breast cancers, occuring at higher frequency in younger women and has a disproportionately higher mortality compared to other breast cancer subtypes. They are often resistant to chemotherapy and there are currently no established therapeutic targets to enhance or replace conventional treatment. My study aims to identify novel targets and therapeutic strategies for this aggressive breast cancer subtype, in the hope of improving patient outcomes.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2016

Funding Scheme: Early Career Fellowships

Funding Amount: $365,875.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

breast cancer | cancer biology | cancer chemotherapy | cancer treatment | clinical trial | drug resistance

Related Links